nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—TYMS—ovarian cancer	0.704	1	CbGaD
Pralatrexate—Neoplasm malignant—Altretamine—ovarian cancer	0.00529	0.0474	CcSEcCtD
Pralatrexate—FPGS—myometrium—ovarian cancer	0.00436	0.0593	CbGeAlD
Pralatrexate—SLC19A1—gonad—ovarian cancer	0.00427	0.0581	CbGeAlD
Pralatrexate—SLC19A1—female reproductive system—ovarian cancer	0.00381	0.0519	CbGeAlD
Pralatrexate—FPGS—decidua—ovarian cancer	0.00323	0.044	CbGeAlD
Pralatrexate—SLC19A1—testis—ovarian cancer	0.00308	0.0419	CbGeAlD
Pralatrexate—FPGS—endometrium—ovarian cancer	0.00307	0.0418	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Paclitaxel—ovarian cancer	0.00296	0.0265	CcSEcCtD
Pralatrexate—DHFR—myometrium—ovarian cancer	0.00283	0.0385	CbGeAlD
Pralatrexate—DHFR—embryo—ovarian cancer	0.00272	0.0371	CbGeAlD
Pralatrexate—Pancytopenia—Altretamine—ovarian cancer	0.00269	0.0241	CcSEcCtD
Pralatrexate—Methotrexate—FOLR1—ovarian cancer	0.00255	0.353	CrCbGaD
Pralatrexate—FPGS—female reproductive system—ovarian cancer	0.00254	0.0346	CbGeAlD
Pralatrexate—FPGS—female gonad—ovarian cancer	0.00231	0.0315	CbGeAlD
Pralatrexate—FPGS—vagina—ovarian cancer	0.0023	0.0313	CbGeAlD
Pralatrexate—SLC19A1—lymph node—ovarian cancer	0.00223	0.0304	CbGeAlD
Pralatrexate—TYMS—uterine cervix—ovarian cancer	0.00222	0.0303	CbGeAlD
Pralatrexate—DHFR—uterine cervix—ovarian cancer	0.0022	0.03	CbGeAlD
Pralatrexate—TYMS—Docetaxel—Paclitaxel—ovarian cancer	0.00213	0.472	CbGdCrCtD
Pralatrexate—DHFR—decidua—ovarian cancer	0.0021	0.0286	CbGeAlD
Pralatrexate—FPGS—testis—ovarian cancer	0.00205	0.0279	CbGeAlD
Pralatrexate—TYMS—endometrium—ovarian cancer	0.00201	0.0274	CbGeAlD
Pralatrexate—DHFR—endometrium—ovarian cancer	0.00199	0.0271	CbGeAlD
Pralatrexate—Neoplasm malignant—Chlorambucil—ovarian cancer	0.00188	0.0168	CcSEcCtD
Pralatrexate—TYMS—gonad—ovarian cancer	0.00187	0.0254	CbGeAlD
Pralatrexate—DHFR—gonad—ovarian cancer	0.00185	0.0252	CbGeAlD
Pralatrexate—DHFR—uterus—ovarian cancer	0.00184	0.025	CbGeAlD
Pralatrexate—Anaemia—Altretamine—ovarian cancer	0.00182	0.0164	CcSEcCtD
Pralatrexate—Leukopenia—Altretamine—ovarian cancer	0.00177	0.0158	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Epirubicin—ovarian cancer	0.00169	0.0152	CcSEcCtD
Pralatrexate—Raltitrexed—TYMS—ovarian cancer	0.00168	0.232	CrCbGaD
Pralatrexate—TYMS—female reproductive system—ovarian cancer	0.00167	0.0227	CbGeAlD
Pralatrexate—DHFR—female reproductive system—ovarian cancer	0.00165	0.0225	CbGeAlD
Pralatrexate—Neoplasm malignant—Melphalan—ovarian cancer	0.00164	0.0147	CcSEcCtD
Pralatrexate—Thrombocytopenia—Altretamine—ovarian cancer	0.00158	0.0141	CcSEcCtD
Pralatrexate—TYMS—bone marrow—ovarian cancer	0.00157	0.0214	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—ovarian cancer	0.00157	0.014	CcSEcCtD
Pralatrexate—DHFR—bone marrow—ovarian cancer	0.00156	0.0212	CbGeAlD
Pralatrexate—Anorexia—Altretamine—ovarian cancer	0.00153	0.0138	CcSEcCtD
Pralatrexate—Night sweats—Paclitaxel—ovarian cancer	0.00152	0.0137	CcSEcCtD
Pralatrexate—TYMS—female gonad—ovarian cancer	0.00152	0.0206	CbGeAlD
Pralatrexate—TYMS—vagina—ovarian cancer	0.00151	0.0205	CbGeAlD
Pralatrexate—DHFR—female gonad—ovarian cancer	0.0015	0.0204	CbGeAlD
Pralatrexate—DHFR—vagina—ovarian cancer	0.00149	0.0203	CbGeAlD
Pralatrexate—FPGS—lymph node—ovarian cancer	0.00149	0.0202	CbGeAlD
Pralatrexate—Decreased appetite—Altretamine—ovarian cancer	0.0014	0.0126	CcSEcCtD
Pralatrexate—Fatigue—Altretamine—ovarian cancer	0.00139	0.0124	CcSEcCtD
Pralatrexate—TYMS—testis—ovarian cancer	0.00135	0.0183	CbGeAlD
Pralatrexate—DHFR—testis—ovarian cancer	0.00133	0.0181	CbGeAlD
Pralatrexate—Leucovorin—TYMS—ovarian cancer	0.00127	0.176	CrCbGaD
Pralatrexate—Sepsis—Topotecan—ovarian cancer	0.00124	0.0111	CcSEcCtD
Pralatrexate—Pharyngolaryngeal pain—Paclitaxel—ovarian cancer	0.00122	0.0109	CcSEcCtD
Pralatrexate—Laryngeal pain—Paclitaxel—ovarian cancer	0.00121	0.0108	CcSEcCtD
Pralatrexate—Asthenia—Altretamine—ovarian cancer	0.00116	0.0104	CcSEcCtD
Pralatrexate—TYMS—Paclitaxel—Docetaxel—ovarian cancer	0.00106	0.236	CbGdCrCtD
Pralatrexate—Sepsis—Vinorelbine—ovarian cancer	0.00106	0.00951	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Chlorambucil—ovarian cancer	0.00105	0.0094	CcSEcCtD
Pralatrexate—Pharyngolaryngeal pain—Docetaxel—ovarian cancer	0.00103	0.00925	CcSEcCtD
Pralatrexate—Vomiting—Altretamine—ovarian cancer	0.00102	0.00918	CcSEcCtD
Pralatrexate—Laryngeal pain—Docetaxel—ovarian cancer	0.00102	0.00916	CcSEcCtD
Pralatrexate—Pemetrexed—TYMS—ovarian cancer	0.00102	0.141	CrCbGaD
Pralatrexate—TYMS—lymph node—ovarian cancer	0.000975	0.0133	CbGeAlD
Pralatrexate—DHFR—lymph node—ovarian cancer	0.000965	0.0131	CbGeAlD
Pralatrexate—Nausea—Altretamine—ovarian cancer	0.000956	0.00858	CcSEcCtD
Pralatrexate—Pancytopenia—Chlorambucil—ovarian cancer	0.000956	0.00857	CcSEcCtD
Pralatrexate—Neutropenia—Chlorambucil—ovarian cancer	0.000941	0.00844	CcSEcCtD
Pralatrexate—Liver function test abnormal—Melphalan—ovarian cancer	0.000937	0.0084	CcSEcCtD
Pralatrexate—Body temperature increased—Carboplatin—ovarian cancer	0.000879	0.00789	CcSEcCtD
Pralatrexate—Pancytopenia—Topotecan—ovarian cancer	0.000851	0.00763	CcSEcCtD
Pralatrexate—Neutropenia—Topotecan—ovarian cancer	0.000838	0.00751	CcSEcCtD
Pralatrexate—Pancytopenia—Melphalan—ovarian cancer	0.000833	0.00747	CcSEcCtD
Pralatrexate—Neutropenia—Melphalan—ovarian cancer	0.00082	0.00736	CcSEcCtD
Pralatrexate—Epistaxis—Topotecan—ovarian cancer	0.000753	0.00676	CcSEcCtD
Pralatrexate—TYMS—Vincristine—Vinorelbine—ovarian cancer	0.000731	0.162	CbGdCrCtD
Pralatrexate—Pancytopenia—Vinorelbine—ovarian cancer	0.000728	0.00653	CcSEcCtD
Pralatrexate—Neutropenia—Vinorelbine—ovarian cancer	0.000717	0.00643	CcSEcCtD
Pralatrexate—Sepsis—Paclitaxel—ovarian cancer	0.000713	0.00639	CcSEcCtD
Pralatrexate—Anaemia—Chlorambucil—ovarian cancer	0.000648	0.00581	CcSEcCtD
Pralatrexate—Leukopenia—Chlorambucil—ovarian cancer	0.000628	0.00563	CcSEcCtD
Pralatrexate—Sepsis—Docetaxel—ovarian cancer	0.000604	0.00542	CcSEcCtD
Pralatrexate—Back pain—Topotecan—ovarian cancer	0.000604	0.00541	CcSEcCtD
Pralatrexate—Pain in extremity—Paclitaxel—ovarian cancer	0.000596	0.00535	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vinorelbine—ovarian cancer	0.000588	0.13	CbGdCrCtD
Pralatrexate—Anaemia—Topotecan—ovarian cancer	0.000577	0.00517	CcSEcCtD
Pralatrexate—Anaemia—Melphalan—ovarian cancer	0.000565	0.00507	CcSEcCtD
Pralatrexate—Methotrexate—TYMS—ovarian cancer	0.000561	0.0777	CrCbGaD
Pralatrexate—Thrombocytopenia—Chlorambucil—ovarian cancer	0.00056	0.00502	CcSEcCtD
Pralatrexate—Leukopenia—Topotecan—ovarian cancer	0.000559	0.00501	CcSEcCtD
Pralatrexate—Dehydration—Paclitaxel—ovarian cancer	0.000555	0.00497	CcSEcCtD
Pralatrexate—Liver function test abnormal—Paclitaxel—ovarian cancer	0.000551	0.00494	CcSEcCtD
Pralatrexate—Neoplasm malignant—Epirubicin—ovarian cancer	0.00055	0.00493	CcSEcCtD
Pralatrexate—Leukopenia—Melphalan—ovarian cancer	0.000547	0.00491	CcSEcCtD
Pralatrexate—Anorexia—Chlorambucil—ovarian cancer	0.000545	0.00489	CcSEcCtD
Pralatrexate—Cough—Topotecan—ovarian cancer	0.000545	0.00488	CcSEcCtD
Pralatrexate—Hypokalaemia—Paclitaxel—ovarian cancer	0.000543	0.00487	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Paclitaxel—ovarian cancer	0.000537	0.00482	CcSEcCtD
Pralatrexate—Cough—Melphalan—ovarian cancer	0.000533	0.00478	CcSEcCtD
Pralatrexate—Back pain—Vinorelbine—ovarian cancer	0.000517	0.00463	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—ovarian cancer	0.000509	0.00456	CcSEcCtD
Pralatrexate—Pain in extremity—Docetaxel—ovarian cancer	0.000506	0.00453	CcSEcCtD
Pralatrexate—Oedema—Melphalan—ovarian cancer	0.000499	0.00447	CcSEcCtD
Pralatrexate—Thrombocytopenia—Topotecan—ovarian cancer	0.000499	0.00447	CcSEcCtD
Pralatrexate—Decreased appetite—Chlorambucil—ovarian cancer	0.000497	0.00446	CcSEcCtD
Pralatrexate—Anaemia—Vinorelbine—ovarian cancer	0.000494	0.00443	CcSEcCtD
Pralatrexate—Fatigue—Chlorambucil—ovarian cancer	0.000493	0.00442	CcSEcCtD
Pralatrexate—Pancytopenia—Paclitaxel—ovarian cancer	0.00049	0.00439	CcSEcCtD
Pralatrexate—Thrombocytopenia—Melphalan—ovarian cancer	0.000488	0.00438	CcSEcCtD
Pralatrexate—Tachycardia—Melphalan—ovarian cancer	0.000487	0.00437	CcSEcCtD
Pralatrexate—Anorexia—Topotecan—ovarian cancer	0.000486	0.00435	CcSEcCtD
Pralatrexate—Neutropenia—Paclitaxel—ovarian cancer	0.000482	0.00432	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000479	0.0043	CcSEcCtD
Pralatrexate—Leukopenia—Vinorelbine—ovarian cancer	0.000478	0.00429	CcSEcCtD
Pralatrexate—Anorexia—Melphalan—ovarian cancer	0.000475	0.00426	CcSEcCtD
Pralatrexate—Dehydration—Docetaxel—ovarian cancer	0.00047	0.00422	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000468	0.0042	CcSEcCtD
Pralatrexate—Liver function test abnormal—Docetaxel—ovarian cancer	0.000467	0.00419	CcSEcCtD
Pralatrexate—Cough—Vinorelbine—ovarian cancer	0.000466	0.00418	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Docetaxel—ovarian cancer	0.000455	0.00408	CcSEcCtD
Pralatrexate—Dyspnoea—Topotecan—ovarian cancer	0.000454	0.00407	CcSEcCtD
Pralatrexate—Abdominal pain—Chlorambucil—ovarian cancer	0.000452	0.00406	CcSEcCtD
Pralatrexate—Body temperature increased—Chlorambucil—ovarian cancer	0.000452	0.00406	CcSEcCtD
Pralatrexate—Dyspnoea—Melphalan—ovarian cancer	0.000445	0.00399	CcSEcCtD
Pralatrexate—Decreased appetite—Topotecan—ovarian cancer	0.000443	0.00397	CcSEcCtD
Pralatrexate—Fatigue—Topotecan—ovarian cancer	0.000439	0.00394	CcSEcCtD
Pralatrexate—Constipation—Topotecan—ovarian cancer	0.000436	0.00391	CcSEcCtD
Pralatrexate—Decreased appetite—Melphalan—ovarian cancer	0.000434	0.00389	CcSEcCtD
Pralatrexate—Epistaxis—Paclitaxel—ovarian cancer	0.000433	0.00389	CcSEcCtD
Pralatrexate—Fatigue—Melphalan—ovarian cancer	0.00043	0.00386	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000427	0.00383	CcSEcCtD
Pralatrexate—Tachycardia—Vinorelbine—ovarian cancer	0.000425	0.00381	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Topotecan—ovarian cancer	0.000417	0.00374	CcSEcCtD
Pralatrexate—Anorexia—Vinorelbine—ovarian cancer	0.000415	0.00373	CcSEcCtD
Pralatrexate—Pancytopenia—Docetaxel—ovarian cancer	0.000415	0.00372	CcSEcCtD
Pralatrexate—Asthenia—Chlorambucil—ovarian cancer	0.000411	0.00368	CcSEcCtD
Pralatrexate—Neutropenia—Docetaxel—ovarian cancer	0.000409	0.00366	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—ovarian cancer	0.000408	0.00366	CcSEcCtD
Pralatrexate—Pruritus—Chlorambucil—ovarian cancer	0.000405	0.00363	CcSEcCtD
Pralatrexate—Abdominal pain—Topotecan—ovarian cancer	0.000403	0.00361	CcSEcCtD
Pralatrexate—Body temperature increased—Topotecan—ovarian cancer	0.000403	0.00361	CcSEcCtD
Pralatrexate—Diarrhoea—Chlorambucil—ovarian cancer	0.000392	0.00351	CcSEcCtD
Pralatrexate—Dyspnoea—Vinorelbine—ovarian cancer	0.000389	0.00348	CcSEcCtD
Pralatrexate—Decreased appetite—Vinorelbine—ovarian cancer	0.000379	0.0034	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—ovarian cancer	0.000377	0.00338	CcSEcCtD
Pralatrexate—Fatigue—Vinorelbine—ovarian cancer	0.000376	0.00337	CcSEcCtD
Pralatrexate—Constipation—Vinorelbine—ovarian cancer	0.000373	0.00334	CcSEcCtD
Pralatrexate—Epistaxis—Docetaxel—ovarian cancer	0.000367	0.0033	CcSEcCtD
Pralatrexate—Asthenia—Topotecan—ovarian cancer	0.000366	0.00328	CcSEcCtD
Pralatrexate—Vomiting—Chlorambucil—ovarian cancer	0.000364	0.00326	CcSEcCtD
Pralatrexate—Pruritus—Topotecan—ovarian cancer	0.00036	0.00323	CcSEcCtD
Pralatrexate—Asthenia—Melphalan—ovarian cancer	0.000358	0.00321	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000356	0.0032	CcSEcCtD
Pralatrexate—Pruritus—Melphalan—ovarian cancer	0.000353	0.00316	CcSEcCtD
Pralatrexate—Diarrhoea—Topotecan—ovarian cancer	0.000349	0.00313	CcSEcCtD
Pralatrexate—Back pain—Paclitaxel—ovarian cancer	0.000347	0.00312	CcSEcCtD
Pralatrexate—Abdominal pain—Vinorelbine—ovarian cancer	0.000344	0.00309	CcSEcCtD
Pralatrexate—Body temperature increased—Vinorelbine—ovarian cancer	0.000344	0.00309	CcSEcCtD
Pralatrexate—Diarrhoea—Melphalan—ovarian cancer	0.000341	0.00306	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—ovarian cancer	0.000341	0.00306	CcSEcCtD
Pralatrexate—Nausea—Chlorambucil—ovarian cancer	0.00034	0.00305	CcSEcCtD
Pralatrexate—Anaemia—Paclitaxel—ovarian cancer	0.000332	0.00298	CcSEcCtD
Pralatrexate—Vomiting—Topotecan—ovarian cancer	0.000324	0.0029	CcSEcCtD
Pralatrexate—Leukopenia—Paclitaxel—ovarian cancer	0.000321	0.00288	CcSEcCtD
Pralatrexate—Rash—Topotecan—ovarian cancer	0.000321	0.00288	CcSEcCtD
Pralatrexate—Dermatitis—Topotecan—ovarian cancer	0.000321	0.00288	CcSEcCtD
Pralatrexate—Vomiting—Melphalan—ovarian cancer	0.000317	0.00284	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—ovarian cancer	0.000317	0.00284	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—ovarian cancer	0.000315	0.00283	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—ovarian cancer	0.000315	0.00282	CcSEcCtD
Pralatrexate—Rash—Melphalan—ovarian cancer	0.000315	0.00282	CcSEcCtD
Pralatrexate—Dermatitis—Melphalan—ovarian cancer	0.000314	0.00282	CcSEcCtD
Pralatrexate—Cough—Paclitaxel—ovarian cancer	0.000313	0.00281	CcSEcCtD
Pralatrexate—Asthenia—Vinorelbine—ovarian cancer	0.000313	0.0028	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—ovarian cancer	0.00031	0.00278	CcSEcCtD
Pralatrexate—Pruritus—Vinorelbine—ovarian cancer	0.000308	0.00277	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000307	0.00275	CcSEcCtD
Pralatrexate—Nausea—Topotecan—ovarian cancer	0.000303	0.00271	CcSEcCtD
Pralatrexate—Diarrhoea—Vinorelbine—ovarian cancer	0.000298	0.00267	CcSEcCtD
Pralatrexate—Nausea—Melphalan—ovarian cancer	0.000296	0.00266	CcSEcCtD
Pralatrexate—Back pain—Docetaxel—ovarian cancer	0.000294	0.00264	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—ovarian cancer	0.000293	0.00263	CcSEcCtD
Pralatrexate—Oedema—Paclitaxel—ovarian cancer	0.000293	0.00263	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000291	0.00261	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—ovarian cancer	0.000287	0.00257	CcSEcCtD
Pralatrexate—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000287	0.00257	CcSEcCtD
Pralatrexate—Tachycardia—Paclitaxel—ovarian cancer	0.000286	0.00257	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000284	0.00255	CcSEcCtD
Pralatrexate—Anaemia—Docetaxel—ovarian cancer	0.000281	0.00252	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—ovarian cancer	0.00028	0.00251	CcSEcCtD
Pralatrexate—Anorexia—Paclitaxel—ovarian cancer	0.000279	0.00251	CcSEcCtD
Pralatrexate—Vomiting—Vinorelbine—ovarian cancer	0.000277	0.00248	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—ovarian cancer	0.000276	0.00247	CcSEcCtD
Pralatrexate—Rash—Vinorelbine—ovarian cancer	0.000275	0.00246	CcSEcCtD
Pralatrexate—Dermatitis—Vinorelbine—ovarian cancer	0.000275	0.00246	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000274	0.00246	CcSEcCtD
Pralatrexate—Leukopenia—Docetaxel—ovarian cancer	0.000272	0.00244	CcSEcCtD
Pralatrexate—Cough—Docetaxel—ovarian cancer	0.000266	0.00238	CcSEcCtD
Pralatrexate—Dyspnoea—Paclitaxel—ovarian cancer	0.000261	0.00234	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—ovarian cancer	0.000259	0.00232	CcSEcCtD
Pralatrexate—Nausea—Vinorelbine—ovarian cancer	0.000259	0.00232	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—ovarian cancer	0.000255	0.00229	CcSEcCtD
Pralatrexate—Decreased appetite—Paclitaxel—ovarian cancer	0.000255	0.00229	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000253	0.00227	CcSEcCtD
Pralatrexate—Fatigue—Paclitaxel—ovarian cancer	0.000253	0.00227	CcSEcCtD
Pralatrexate—Constipation—Paclitaxel—ovarian cancer	0.000251	0.00225	CcSEcCtD
Pralatrexate—Oedema—Docetaxel—ovarian cancer	0.000248	0.00223	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—ovarian cancer	0.000248	0.00222	CcSEcCtD
Pralatrexate—Thrombocytopenia—Docetaxel—ovarian cancer	0.000243	0.00218	CcSEcCtD
Pralatrexate—Tachycardia—Docetaxel—ovarian cancer	0.000242	0.00217	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00024	0.00215	CcSEcCtD
Pralatrexate—Anorexia—Docetaxel—ovarian cancer	0.000237	0.00212	CcSEcCtD
Pralatrexate—Body temperature increased—Paclitaxel—ovarian cancer	0.000232	0.00208	CcSEcCtD
Pralatrexate—Abdominal pain—Paclitaxel—ovarian cancer	0.000232	0.00208	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—ovarian cancer	0.000229	0.00206	CcSEcCtD
Pralatrexate—Dyspnoea—Docetaxel—ovarian cancer	0.000222	0.00199	CcSEcCtD
Pralatrexate—Decreased appetite—Docetaxel—ovarian cancer	0.000216	0.00194	CcSEcCtD
Pralatrexate—Fatigue—Docetaxel—ovarian cancer	0.000214	0.00192	CcSEcCtD
Pralatrexate—Constipation—Docetaxel—ovarian cancer	0.000212	0.00191	CcSEcCtD
Pralatrexate—Asthenia—Paclitaxel—ovarian cancer	0.00021	0.00189	CcSEcCtD
Pralatrexate—Pruritus—Paclitaxel—ovarian cancer	0.000207	0.00186	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000203	0.00182	CcSEcCtD
Pralatrexate—Diarrhoea—Paclitaxel—ovarian cancer	0.000201	0.0018	CcSEcCtD
Pralatrexate—Back pain—Epirubicin—ovarian cancer	0.000199	0.00178	CcSEcCtD
Pralatrexate—Body temperature increased—Docetaxel—ovarian cancer	0.000196	0.00176	CcSEcCtD
Pralatrexate—Abdominal pain—Docetaxel—ovarian cancer	0.000196	0.00176	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—ovarian cancer	0.00019	0.0017	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—YAP1—ovarian cancer	0.000189	0.00191	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—ovarian cancer	0.000189	0.00191	CbGpPWpGaD
Pralatrexate—FPGS—Disease—XIAP—ovarian cancer	0.000188	0.0019	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	0.000188	0.00189	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—RBL2—ovarian cancer	0.000187	0.00188	CbGpPWpGaD
Pralatrexate—Vomiting—Paclitaxel—ovarian cancer	0.000186	0.00167	CcSEcCtD
Pralatrexate—DHFR—Disease—CHMP4C—ovarian cancer	0.000186	0.00187	CbGpPWpGaD
Pralatrexate—Rash—Paclitaxel—ovarian cancer	0.000185	0.00166	CcSEcCtD
Pralatrexate—Dermatitis—Paclitaxel—ovarian cancer	0.000185	0.00166	CcSEcCtD
Pralatrexate—SLC19A1—Disease—FASN—ovarian cancer	0.000184	0.00186	CbGpPWpGaD
Pralatrexate—Leukopenia—Epirubicin—ovarian cancer	0.000184	0.00165	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—ovarian cancer	0.000184	0.00165	CcSEcCtD
Pralatrexate—SLC19A1—Disease—PARP1—ovarian cancer	0.000184	0.00185	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SMARCA4—ovarian cancer	0.000184	0.00185	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—CDKN1B—ovarian cancer	0.00018	0.00181	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EREG—ovarian cancer	0.000179	0.0018	CbGpPWpGaD
Pralatrexate—Cough—Epirubicin—ovarian cancer	0.000179	0.00161	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	0.000179	0.0018	CbGpPWpGaD
Pralatrexate—Asthenia—Docetaxel—ovarian cancer	0.000178	0.0016	CcSEcCtD
Pralatrexate—DHFR—Metabolism—NME2—ovarian cancer	0.000178	0.00179	CbGpPWpGaD
Pralatrexate—Pruritus—Docetaxel—ovarian cancer	0.000176	0.00158	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—ovarian cancer	0.000176	0.00157	CcSEcCtD
Pralatrexate—SLC19A1—Disease—SLC2A1—ovarian cancer	0.000175	0.00176	CbGpPWpGaD
Pralatrexate—Nausea—Paclitaxel—ovarian cancer	0.000174	0.00156	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—ovarian cancer	0.00017	0.00153	CcSEcCtD
Pralatrexate—Diarrhoea—Docetaxel—ovarian cancer	0.00017	0.00152	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—ovarian cancer	0.000169	0.0017	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—ovarian cancer	0.000168	0.0015	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—ovarian cancer	0.000166	0.00149	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—ovarian cancer	0.000165	0.00166	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000165	0.00166	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Epirubicin—ovarian cancer	0.000164	0.00147	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—ovarian cancer	0.000164	0.00147	CcSEcCtD
Pralatrexate—DHFR—Disease—BCL9—ovarian cancer	0.000161	0.00162	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—YAP1—ovarian cancer	0.000161	0.00162	CbGpPWpGaD
Pralatrexate—Anorexia—Epirubicin—ovarian cancer	0.00016	0.00143	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.00016	0.00161	CbGpPWpGaD
Pralatrexate—Vomiting—Docetaxel—ovarian cancer	0.000158	0.00142	CcSEcCtD
Pralatrexate—FPGS—Disease—FASN—ovarian cancer	0.000157	0.00158	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—CDKN1B—ovarian cancer	0.000157	0.00158	CbGpPWpGaD
Pralatrexate—Rash—Docetaxel—ovarian cancer	0.000157	0.0014	CcSEcCtD
Pralatrexate—Dermatitis—Docetaxel—ovarian cancer	0.000157	0.0014	CcSEcCtD
Pralatrexate—FPGS—Disease—PARP1—ovarian cancer	0.000156	0.00157	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NME2—ovarian cancer	0.000155	0.00157	CbGpPWpGaD
Pralatrexate—Oedema—Doxorubicin—ovarian cancer	0.000155	0.00139	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—FASN—ovarian cancer	0.000154	0.00156	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—IL6—ovarian cancer	0.000154	0.00155	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SLC5A5—ovarian cancer	0.000152	0.00153	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000152	0.00136	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000151	0.00152	CbGpPWpGaD
Pralatrexate—Tachycardia—Doxorubicin—ovarian cancer	0.000151	0.00136	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—ovarian cancer	0.000149	0.00134	CcSEcCtD
Pralatrexate—FPGS—Disease—SLC2A1—ovarian cancer	0.000149	0.0015	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PPP2R1A—ovarian cancer	0.000149	0.0015	CbGpPWpGaD
Pralatrexate—Anorexia—Doxorubicin—ovarian cancer	0.000148	0.00133	CcSEcCtD
Pralatrexate—Nausea—Docetaxel—ovarian cancer	0.000148	0.00132	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000147	0.00148	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—SLC2A1—ovarian cancer	0.000147	0.00148	CbGpPWpGaD
Pralatrexate—Decreased appetite—Epirubicin—ovarian cancer	0.000146	0.00131	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—ovarian cancer	0.000144	0.0013	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000144	0.00145	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MLH1—ovarian cancer	0.000144	0.00145	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	0.000144	0.00145	CbGpPWpGaD
Pralatrexate—Constipation—Epirubicin—ovarian cancer	0.000143	0.00129	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—SKP2—ovarian cancer	0.000143	0.00144	CbGpPWpGaD
Pralatrexate—Methotrexate—ABCB1—ovarian cancer	0.000142	0.0197	CrCbGaD
Pralatrexate—SLC19A1—Metabolism—CYP1B1—ovarian cancer	0.000141	0.00142	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—SKP2—ovarian cancer	0.000139	0.0014	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000139	0.0014	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—ovarian cancer	0.000138	0.00124	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—MYC—ovarian cancer	0.000137	0.00138	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000137	0.00123	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000135	0.00136	CbGpPWpGaD
Pralatrexate—Decreased appetite—Doxorubicin—ovarian cancer	0.000135	0.00121	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—ovarian cancer	0.000134	0.0012	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—ovarian cancer	0.000133	0.00119	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—ovarian cancer	0.000132	0.00119	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—ovarian cancer	0.000132	0.00119	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	0.000132	0.00133	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—FASN—ovarian cancer	0.000131	0.00132	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—SLC5A5—ovarian cancer	0.000129	0.0013	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000127	0.00114	CcSEcCtD
Pralatrexate—FPGS—Disease—PPP2R1A—ovarian cancer	0.000127	0.00128	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—ovarian cancer	0.000126	0.00127	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MLH1—ovarian cancer	0.000126	0.00127	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—SLC2A1—ovarian cancer	0.000125	0.00126	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PPP2R1A—ovarian cancer	0.000125	0.00126	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—SKP2—ovarian cancer	0.000124	0.00125	CbGpPWpGaD
Pralatrexate—Body temperature increased—Doxorubicin—ovarian cancer	0.000123	0.0011	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—ovarian cancer	0.000123	0.0011	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000122	0.00123	CbGpPWpGaD
Pralatrexate—Asthenia—Epirubicin—ovarian cancer	0.00012	0.00108	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—MYC—ovarian cancer	0.00012	0.00121	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PPP1CC—ovarian cancer	0.00012	0.00121	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CYP1B1—ovarian cancer	0.00012	0.0012	CbGpPWpGaD
Pralatrexate—Pruritus—Epirubicin—ovarian cancer	0.000119	0.00106	CcSEcCtD
Pralatrexate—SLC19A1—Disease—TERT—ovarian cancer	0.000118	0.00119	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	0.000118	0.00119	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CHEK2—ovarian cancer	0.000117	0.00117	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ABCB1—ovarian cancer	0.000116	0.00117	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000116	0.00117	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000115	0.00116	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYTB—ovarian cancer	0.000115	0.00116	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—ovarian cancer	0.000115	0.00103	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—TYMS—ovarian cancer	0.000114	0.00115	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—ovarian cancer	0.000111	0.000998	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—ovarian cancer	0.00011	0.000984	CcSEcCtD
Pralatrexate—SLC19A1—Disease—CAV1—ovarian cancer	0.000109	0.0011	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND2—ovarian cancer	0.000109	0.0011	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BRCA1—ovarian cancer	0.000109	0.0011	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000108	0.00109	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCNE1—ovarian cancer	0.000107	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND2—ovarian cancer	0.000107	0.00107	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—ovarian cancer	0.000107	0.000956	CcSEcCtD
Pralatrexate—Diarrhoea—Doxorubicin—ovarian cancer	0.000106	0.000951	CcSEcCtD
Pralatrexate—FPGS—Metabolism—PPP2R1A—ovarian cancer	0.000106	0.00107	CbGpPWpGaD
Pralatrexate—Rash—Epirubicin—ovarian cancer	0.000106	0.000948	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—ovarian cancer	0.000106	0.000947	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TYMS—ovarian cancer	0.000105	0.00106	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6ST—ovarian cancer	0.000104	0.00104	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—PPP2R1A—ovarian cancer	0.000103	0.00104	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CHEK2—ovarian cancer	0.000102	0.00103	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—ovarian cancer	0.000101	0.00102	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	0.000101	0.00101	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TERT—ovarian cancer	0.000101	0.00101	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPP1CC—ovarian cancer	0.0001	0.00101	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BRIP1—ovarian cancer	0.0001	0.00101	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYTB—ovarian cancer	0.0001	0.00101	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.0001	0.00101	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APC—ovarian cancer	9.97e-05	0.001	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—ovarian cancer	9.95e-05	0.000893	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—BRCA2—ovarian cancer	9.89e-05	0.000996	CbGpPWpGaD
Pralatrexate—Vomiting—Doxorubicin—ovarian cancer	9.86e-05	0.000884	CcSEcCtD
Pralatrexate—FPGS—Metabolism—ABCB1—ovarian cancer	9.85e-05	0.000992	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	9.81e-05	0.000988	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—ovarian cancer	9.78e-05	0.000877	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—ovarian cancer	9.77e-05	0.000876	CcSEcCtD
Pralatrexate—FPGS—Metabolism—TYMS—ovarian cancer	9.67e-05	0.000974	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCNE1—ovarian cancer	9.58e-05	0.000964	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	9.55e-05	0.000961	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND2—ovarian cancer	9.54e-05	0.000961	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BRCA1—ovarian cancer	9.54e-05	0.000961	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BIRC5—ovarian cancer	9.46e-05	0.000953	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	9.45e-05	0.000952	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TYMS—ovarian cancer	9.41e-05	0.000947	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCNE1—ovarian cancer	9.35e-05	0.000941	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CAV1—ovarian cancer	9.31e-05	0.000937	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	9.22e-05	0.000928	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—ovarian cancer	9.21e-05	0.000826	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CAV1—ovarian cancer	9.17e-05	0.000923	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HDAC6—ovarian cancer	9.08e-05	0.000914	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—PPP2R1A—ovarian cancer	9e-05	0.000906	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PTEN—ovarian cancer	8.85e-05	0.000891	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6ST—ovarian cancer	8.82e-05	0.000888	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CD—ovarian cancer	8.77e-05	0.000883	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPP1CC—ovarian cancer	8.76e-05	0.000882	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BRIP1—ovarian cancer	8.76e-05	0.000882	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BRCA2—ovarian cancer	8.63e-05	0.000869	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APC—ovarian cancer	8.48e-05	0.000854	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BIRC5—ovarian cancer	8.46e-05	0.000852	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCNE1—ovarian cancer	8.36e-05	0.000841	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CG—ovarian cancer	8.35e-05	0.000841	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	8.32e-05	0.000838	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BIRC5—ovarian cancer	8.25e-05	0.000831	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TERT—ovarian cancer	8.19e-05	0.000825	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	7.87e-05	0.000793	CbGpPWpGaD
Pralatrexate—DHFR—Disease—XIAP—ovarian cancer	7.87e-05	0.000793	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CAV1—ovarian cancer	7.8e-05	0.000785	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—ovarian cancer	7.74e-05	0.00078	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SMARCA4—ovarian cancer	7.67e-05	0.000773	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	7.66e-05	0.000771	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CB—ovarian cancer	7.64e-05	0.000769	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MTOR—ovarian cancer	7.64e-05	0.000769	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	7.49e-05	0.000754	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	7.49e-05	0.000754	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EREG—ovarian cancer	7.49e-05	0.000754	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CD—ovarian cancer	7.45e-05	0.00075	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BIRC5—ovarian cancer	7.38e-05	0.000743	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CD—ovarian cancer	7.34e-05	0.000739	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1B—ovarian cancer	7.17e-05	0.000722	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TERT—ovarian cancer	7.15e-05	0.00072	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CG—ovarian cancer	7.1e-05	0.000715	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.08e-05	0.000712	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—ovarian cancer	6.77e-05	0.000682	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—YAP1—ovarian cancer	6.73e-05	0.000678	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTEN—ovarian cancer	6.6e-05	0.000665	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—ovarian cancer	6.58e-05	0.000663	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FASN—ovarian cancer	6.55e-05	0.00066	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PARP1—ovarian cancer	6.52e-05	0.000657	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.5e-05	0.000655	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CB—ovarian cancer	6.5e-05	0.000654	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MTOR—ovarian cancer	6.5e-05	0.000654	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CB—ovarian cancer	6.4e-05	0.000644	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.29e-05	0.000633	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CD—ovarian cancer	6.24e-05	0.000629	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC2A1—ovarian cancer	6.22e-05	0.000627	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1B—ovarian cancer	6.1e-05	0.000614	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—ovarian cancer	6.04e-05	0.000608	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—STAT3—ovarian cancer	5.9e-05	0.000595	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—ovarian cancer	5.89e-05	0.000593	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—YAP1—ovarian cancer	5.87e-05	0.000591	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—ovarian cancer	5.76e-05	0.00058	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MAPK3—ovarian cancer	5.64e-05	0.000568	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTEN—ovarian cancer	5.61e-05	0.000565	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	5.55e-05	0.000559	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTEN—ovarian cancer	5.53e-05	0.000557	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—IL6—ovarian cancer	5.53e-05	0.000556	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—ovarian cancer	5.49e-05	0.000552	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—FASN—ovarian cancer	5.49e-05	0.000552	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CB—ovarian cancer	5.44e-05	0.000548	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC5A5—ovarian cancer	5.4e-05	0.000543	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MAPK1—ovarian cancer	5.37e-05	0.00054	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—ovarian cancer	5.37e-05	0.00054	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.31e-05	0.000535	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—ovarian cancer	5.3e-05	0.000533	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PPP2R1A—ovarian cancer	5.29e-05	0.000533	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC2A1—ovarian cancer	5.21e-05	0.000525	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—ovarian cancer	5.07e-05	0.00051	CbGpPWpGaD
Pralatrexate—FPGS—Disease—STAT3—ovarian cancer	5.02e-05	0.000506	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—ovarian cancer	5.01e-05	0.000504	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CYP1B1—ovarian cancer	5e-05	0.000503	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1B—ovarian cancer	4.96e-05	0.0005	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	4.84e-05	0.000488	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MAPK3—ovarian cancer	4.8e-05	0.000483	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—FASN—ovarian cancer	4.79e-05	0.000482	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—ovarian cancer	4.74e-05	0.000477	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC5A5—ovarian cancer	4.71e-05	0.000474	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTEN—ovarian cancer	4.7e-05	0.000473	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—ovarian cancer	4.67e-05	0.00047	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—ovarian cancer	4.66e-05	0.000469	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—ovarian cancer	4.62e-05	0.000465	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MAPK1—ovarian cancer	4.56e-05	0.00046	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—ovarian cancer	4.56e-05	0.000459	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC2A1—ovarian cancer	4.55e-05	0.000458	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPP2R1A—ovarian cancer	4.43e-05	0.000446	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAPK3—ovarian cancer	4.37e-05	0.00044	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CYP1B1—ovarian cancer	4.36e-05	0.000439	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1B—ovarian cancer	4.33e-05	0.000436	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—ovarian cancer	4.31e-05	0.000434	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—ovarian cancer	4.31e-05	0.000434	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—ovarian cancer	4.25e-05	0.000428	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TERT—ovarian cancer	4.2e-05	0.000423	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MAPK1—ovarian cancer	4.16e-05	0.000419	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—ovarian cancer	4.13e-05	0.000416	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—IL6—ovarian cancer	4.12e-05	0.000415	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ABCB1—ovarian cancer	4.11e-05	0.000414	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMS—ovarian cancer	4.04e-05	0.000407	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—ovarian cancer	3.96e-05	0.000399	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAPK3—ovarian cancer	3.91e-05	0.000393	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—ovarian cancer	3.9e-05	0.000393	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CAV1—ovarian cancer	3.89e-05	0.000392	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPP2R1A—ovarian cancer	3.87e-05	0.000389	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAPK3—ovarian cancer	3.81e-05	0.000384	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—ovarian cancer	3.81e-05	0.000383	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—ovarian cancer	3.8e-05	0.000383	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MAPK1—ovarian cancer	3.72e-05	0.000374	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—ovarian cancer	3.71e-05	0.000373	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6ST—ovarian cancer	3.69e-05	0.000371	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—ovarian cancer	3.66e-05	0.000369	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MAPK1—ovarian cancer	3.63e-05	0.000365	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCB1—ovarian cancer	3.59e-05	0.000362	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APC—ovarian cancer	3.54e-05	0.000357	CbGpPWpGaD
Pralatrexate—FPGS—Disease—IL6—ovarian cancer	3.51e-05	0.000353	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAPK3—ovarian cancer	3.41e-05	0.000343	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—ovarian cancer	3.32e-05	0.000334	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—ovarian cancer	3.31e-05	0.000334	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CAV1—ovarian cancer	3.26e-05	0.000328	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MAPK1—ovarian cancer	3.24e-05	0.000327	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—ovarian cancer	3.24e-05	0.000326	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—ovarian cancer	3.19e-05	0.000321	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—ovarian cancer	3.12e-05	0.000314	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CD—ovarian cancer	3.11e-05	0.000314	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CG—ovarian cancer	2.97e-05	0.000299	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CAV1—ovarian cancer	2.84e-05	0.000286	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—ovarian cancer	2.75e-05	0.000277	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—ovarian cancer	2.72e-05	0.000274	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MTOR—ovarian cancer	2.71e-05	0.000273	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CB—ovarian cancer	2.71e-05	0.000273	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—ovarian cancer	2.71e-05	0.000273	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CD—ovarian cancer	2.61e-05	0.000263	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CG—ovarian cancer	2.59e-05	0.000261	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1B—ovarian cancer	2.55e-05	0.000256	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—ovarian cancer	2.41e-05	0.000242	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTEN—ovarian cancer	2.35e-05	0.000236	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CD—ovarian cancer	2.28e-05	0.000229	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CB—ovarian cancer	2.27e-05	0.000229	CbGpPWpGaD
Pralatrexate—DHFR—Disease—STAT3—ovarian cancer	2.1e-05	0.000211	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—ovarian cancer	2.09e-05	0.000211	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAPK3—ovarian cancer	2e-05	0.000202	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CB—ovarian cancer	1.98e-05	0.0002	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTEN—ovarian cancer	1.96e-05	0.000198	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—ovarian cancer	1.95e-05	0.000196	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MAPK1—ovarian cancer	1.91e-05	0.000192	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—ovarian cancer	1.91e-05	0.000192	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—ovarian cancer	1.8e-05	0.000181	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTEN—ovarian cancer	1.71e-05	0.000173	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—ovarian cancer	1.65e-05	0.000167	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—ovarian cancer	1.53e-05	0.000154	CbGpPWpGaD
Pralatrexate—DHFR—Disease—IL6—ovarian cancer	1.46e-05	0.000148	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—ovarian cancer	1.39e-05	0.00014	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—ovarian cancer	1.35e-05	0.000136	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—ovarian cancer	1.21e-05	0.000122	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—ovarian cancer	1.13e-05	0.000114	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—ovarian cancer	9.88e-06	9.94e-05	CbGpPWpGaD
